A mixed treatment comparison of toxicity of gemcitabine combined with different targeted drugs in the treatment of advanced or metastatic pancreatic cancer

References

• Goncalves A, Gilabert M, Francois E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012;23(11):2799–805. doi:10.1093/annonc/mds135. PMID:22771827.
   PubMed Web of Science ®Google Scholar
• Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: A systematic review and network meta-analysis. BMC Cancer. 2014;14:471. doi:10.1186/1471-2407-14-471. PMID:24972449.
   PubMed Web of Science ®Google Scholar
• Ioka T, Okusaka T, Ohkawa S, Boku N, Sawaki A, Fujii Y, Kamei Y, Takahashi S, Namazu K, Umeyama Y, et al. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial. Jpn J Clin Oncol. 2015;45(5):439–48. doi:10.1093/jjco/hyv011. PMID:25647781.
   PubMed Web of Science ®Google Scholar
• Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, Oh DY, Liu Y, Redhu S, Steplewski K, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 2014;50(12):2072–81. doi:10.1016/j.ejca.2014.04.024. PMID:24915778.
   PubMed Web of Science ®Google Scholar
• Lu C, Xu CF, Wan XY, Zhu HT, Yu CH, Li YM. Screening for pancreatic cancer in familial high-risk individuals: A systematic review. World J Gastroenterol. 2015;21(28):8678–86. doi:10.3748/wjg.v21.i28.8678. PMID:26229410.
   PubMed Web of Science ®Google Scholar
• Valenzuela MM, Neidigh JW, Wall NR. Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy (Los Angel). 2014;3(3):137. PMID:26161298.
   PubMedGoogle Scholar
• Asuthkar S, Rao JS, Gondi CS. Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opin Investig Drugs. 2012;21(2):143–52. doi:10.1517/13543784.2012.651124. PMID:22217246.
   PubMed Web of Science ®Google Scholar
• Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev. 2014;40(9):1039–47. doi:10.1016/j.ctrv.2014.07.003. PMID:25087471.
   PubMed Web of Science ®Google Scholar
• Burris HA r, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403–13. doi:10.1200/JCO.1997.15.6.2403. PMID:9196156.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22(8):1430–8. doi:10.1200/JCO.2004.10.112. PMID:15084616.
   PubMed Web of Science ®Google Scholar
• Sofuni A, Itoi T, Itokawa F, Tsuchiya T, Kurihara T, Ishii K, Tsuji S, Ikeuchi N, Moriyasu F. Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy. World J Gastroenterol. 2008;14(47):7183–91. doi:10.3748/wjg.14.7183. PMID:19084932.
   PubMed Web of Science ®Google Scholar
• Lee HS, Park SW. Systemic Chemotherapy in Advanced Pancreatic Cancer. Gut Liver. 2016;10(3):340–7. doi:10.5009/gnl15465. PMID:27114434.
   PubMed Web of Science ®Google Scholar
• Van Loon K EA, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, et al. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase ii trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014;43:343–9. doi:10.1097/MPA.0000000000000095. PMID:24622062.
   PubMed Web of Science ®Google Scholar
• Funakoshi T, Suzuki M, Tamura K. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis. Cancer Treat Rev. 2014;40(10):1221–9. doi:10.1016/j.ctrv.2014.09.002. PMID:25288497.
   PubMed Web of Science ®Google Scholar
• Chung JH, Lee SW. Assessing the quality of randomized controlled urological trials conducted by korean medical institutions. Korean J Urol. 2013;54(5):289–96. doi:10.4111/kju.2013.54.5.289. PMID:23700493.
   PubMedGoogle Scholar
• Chen LX, Li YL, Ning GZ, Li Y, Wu QL, Guo JX, Shi HY, Wang XB, Zhou Y, Feng SQ. Comparative efficacy and tolerability of three treatments in old people with osteoporotic vertebral compression fracture: a network meta-analysis and systematic review. PLoS One. 2015;10(4):e0123153. doi:10.1371/journal.pone.0123153. PMID:25874802.
   PubMed Web of Science ®Google Scholar
• Tu YK NI, Chambrone L, Lu HK, Faggion CM, Jr. A bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies. Journal of clinical periodontology. 2012;39:303–14. doi:10.1111/j.1600-051X.2011.01844.x. PMID:22393565.
   PubMed Web of Science ®Google Scholar
• Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654. doi:10.1371/journal.pone.0076654. PMID:24098547.
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–71. doi:10.1016/j.jclinepi.2010.03.016. PMID:20688472.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617–22. doi:10.1200/JCO.2010.28.1386. PMID:20606091.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6. doi:10.1200/JCO.2006.07.9525. PMID:17452677.
   PubMed Web of Science ®Google Scholar
• Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Letourneau R, Bajetta E, Pithavala Y, Bycott P, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet. 2008;371(9630):2101–8. doi:10.1016/S0140-6736(08)60661-3. PMID:18514303.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012;30(1):382–6. doi:10.1007/s10637-010-9526-z. PMID:20803052.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev. 2012;38(7):843–53. doi:10.1016/j.ctrv.2011.12.004. PMID:22226241.
   PubMed Web of Science ®Google Scholar
• Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):773–81. doi:10.1016/S1470-2045(12)70270-X. PMID:22805291.
   PubMed Web of Science ®Google Scholar
• Vaubel J, Livingstone E, Schadendorf D, Zimmer L. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash. J Eur Acad Dermatol Venereol. 2014;28(12):1685–9. doi:10.1111/jdv.12365. PMID:24422792.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Li CP, Nowara E, Aprile G, Moore M, Federowicz I, Van Laethem JL, Hsu C, Tham CK, Stemmer SM, et al. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer. 2014;111(11):2067–75. doi:10.1038/bjc.2014.494. PMID:25247318.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Furuse J, Funakoshi A, Ioka T, Yamao K, Ohkawa S, Boku N, Komatsu Y, Nakamori S, Iguchi H, et al. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci. 2011;102(2):425–31. doi:10.1111/j.1349-7006.2010.01810.x. PMID:21175992.
   PubMed Web of Science ®Google Scholar